Glucagon-like peptide-1 (GLP-1) receptor agonist prevents development of tolerance to anti-anxiety effect of ethanol and withdrawal-induced anxiety in rats

Effect of maternal nutrient restriction and melatonin supplementation from mid to late gestation on vascular reactivity of maternal and fetal placental arteries

(2014) P. Shukla et al.   PLACENTA

Common biological mechanisms between bipolar disorder and type 2 diabetes: Focus on inflammation

(2014) Ajaykumar N. Sharma et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

2011 AND 2012 EARLY CAREERS ACHIEVEMENT AWARDS: Placental programming: How the maternal environment can impact placental function1,2

(2013) K. A. Vonnahme et al.   JOURNAL OF ANIMAL SCIENCE

Antipsychotic-like effect of GLP-1 agonist liraglutide but not DPP-IV inhibitor sitagliptin in mouse model for psychosis

(2013) Tejashree S. Dixit et al.   PHYSIOLOGY & BEHAVIOR

The Glucagon-Like Peptide 1 Analogue, Exendin-4, Attenuates the Rewarding Properties of Psychostimulant Drugs in Mice

(2013) Emil Egecioglu et al.   PLoS One

Glucagon-like peptide 1 receptor induced suppression of food intake, and body weight is mediated by central IL-1 and IL-6

(2013) R. Shirazi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Naltrexone (50 mg) Plus Psychotherapy in Alcohol-Dependent Patients: A Meta-Analysis of Randomized Controlled Trials

(2013) Joanna Jarosz et al.   AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE

Diabetic db/db mice exhibit central nervous system and peripheral molecular alterations as seen in neurological disorders

(2013) A Ernst et al.   Translational Psychiatry

Melatonin inhibits nitric oxide signaling by increasing PDE5 phosphorylation in coronary arteries

(2012) Praveen Shukla et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis

(2012) Kerry Hunter et al.   BMC NEUROSCIENCE

Liraglutide: from clinical trials to clinical practice

(2012) S. C. L. Gough   DIABETES OBESITY & METABOLISM

Liraglutide: short-lived effect on gastric emptying-long lasting effects on body weight

(2012) J. Jelsing et al.   DIABETES OBESITY & METABOLISM

Glucagon-like peptide-1 in the rat brain: Distribution of expression and functional implication

(2012) Guibao Gu et al.   JOURNAL OF COMPARATIVE NEUROLOGY

Rosiglitazone treatment reversed depression- but not psychosis-like behavior of db/db diabetic mice

(2012) Ajaykumar N Sharma et al.   JOURNAL OF PSYCHOPHARMACOLOGY

The glucagon-like peptide 1 analogue Exendin-4 attenuates alcohol mediated behaviors in rodents

(2012) Emil Egecioglu et al.   PSYCHONEUROENDOCRINOLOGY

Amelioration of neurodegenerative changes in cellular and rat models of diabetes-related Alzheimer’s disease by exendin-4

(2011) Song Chen et al.   AGE

Psychological and quality of life changes in patients using GLP-1 analogues

(2011) Paul Grant et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

MT2 Receptors Mediate the Inhibitory Effects of Melatonin on Nitric Oxide-Induced Relaxation of Porcine Isolated Coronary Arteries

(2010) R. R. Tunstall et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Neurobehavioral deficits in db/db diabetic mice

(2010) Ajaykumar N. Sharma et al.   PHYSIOLOGY & BEHAVIOR

Tolerance to ethanol sedation and withdrawal hyper-excitability is mediated via neuropeptide Y Y1 and Y5 receptors

(2009) Snehal M. Bhisikar et al.   LIFE SCIENCES

Insulin and Insulin-Like Growth Factor Resistance in Alcoholic Neurodegeneration

(2008) Suzanne M. de la Monte et al.   ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH

Acamprosate: Recent Findings and Future Research Directions

(2008) Karl Mann et al.   ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH